MED-ALLY Acquires Resonetics

MED-ALLY has acquired Resonetics for an undisclosed amount.

Resonetics is a pioneer in advanced engineering and manufacturing solutions for the life sciences industry, specializing in micro manufacturing for medical devices.

Founded in 1987, Resonetics has over 30 years of experience, offering core capabilities such as laser ablating, cutting, drilling, and welding, alongside nitinol shape setting, electropolishing, and fiber optic sensing.

The company operates 14 manufacturing facilities across the United States, Canada, Costa Rica, Israel, and Switzerland, all with ISO-13485:2003 certified quality systems.

This acquisition integrates Resonetics' extensive expertise and technological infrastructure into MED-ALLY.

Resonetics has continuously invested in leading-edge technology, deploying over 500 laser workstations covering a wide spectrum of laser types, from femtosecond to CO2.

This robust capability, combined with a top technical team, enables Resonetics to partner with customers in solving complex medical device manufacturing challenges and innovating future medical technologies.

The strategic rationale behind MED-ALLY's acquisition is to enhance its offerings and expand its footprint within the critical life sciences sector.

By incorporating Resonetics' precision manufacturing and Lightspeed Application Development Labs, MED-ALLY gains significant capabilities in high-value medical device components and services.

The synergy between Resonetics' foundation of quality, speed, and innovation and MED-ALLY's strategic vision is expected to deliver best-in-class value with a customer-centric approach.

The combined entity is poised to accelerate the development and delivery of next-generation medical devices.

This integration is anticipated to strengthen global service capabilities for MedTech companies, providing a more comprehensive and advanced suite of manufacturing solutions.

The acquisition positions the unified organization to meet the evolving demands of the global life sciences market more effectively.